Display options
Cite
Scharplatz M, Puhan MA, Steurer J, et al. Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review. Curr Control Trials Cardiovasc Med. 2005;6:16doi: 10.1186/1468-6708-6-16.
Scharplatz, M., Puhan, M. A., Steurer, J., Perna, A., & Bachmann, L. M. (2005). Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review. Current controlled trials in cardiovascular medicine, 616. https://doi.org/10.1186/1468-6708-6-16
Scharplatz, Madlaina, et al. "Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review." Current controlled trials in cardiovascular medicine vol. 6 (2005): 16. doi: https://doi.org/10.1186/1468-6708-6-16
Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM. Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review. Curr Control Trials Cardiovasc Med. 2005 Oct 24;6:16. doi: 10.1186/1468-6708-6-16. PMID: 16242049; PMCID: PMC1283147.
Copy Download .nbib Format: NLM
Share it on

Curr Control Trials Cardiovasc Med. 2005 Oct 24;6:16. doi: 10.1186/1468-6708-6-16.

Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review.

Current controlled trials in cardiovascular medicine

Madlaina Scharplatz, Milo A Puhan, Johann Steurer, Annalisa Perna, Lucas M Bachmann

Affiliations

  1. Horten Centre for patient oriented research, University of Zurich, Switzerland. [email protected]

PMID: 16242049 PMCID: PMC1283147 DOI: 10.1186/1468-6708-6-16

Abstract

BACKGROUND: Pharmacogenetic testing to individualize ACE inhibitor therapy remains controversial. We conducted a systematic review to assess the effect modification of the insertion/deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE inhibitors for cardiovascular and/or renal disease.

METHODS: Our systematic review involved searching six electronic databases, then contacting the investigators (and pharmaceutical industry representatives) responsible for the creation of these databases. Two reviewers independently selected relevant randomized, placebo-controlled trials and abstracted from each study details on characteristics and quality.

RESULTS: Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors, only four of the eleven studies provided sufficient data to quantify the effect modification by genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate, ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate, due to heterogeneity in ethnicity, clinical domains and outcomes.

CONCLUSION: Lack of sufficient genetic data from the reviewed studies precluded drawing any convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary observations concerning better response to ACE inhibitors among Caucasian DD carriers as compared to II carriers.

References

  1. Cardiovasc Drugs Ther. 2000 Feb;14(1):55-60 - PubMed
  2. Kidney Int. 2000 Aug;58(2):889-97 - PubMed
  3. Kidney Int. 2000 Jan;57(1):274-81 - PubMed
  4. J Mol Med (Berl). 1999 Nov;77(11):781-91 - PubMed
  5. Angiology. 1999 Oct;50(10):811-22 - PubMed
  6. QJM. 2001 Feb;94(2):89-94 - PubMed
  7. Lancet. 2001 Apr 28;357(9265):1321-4 - PubMed
  8. Ann Intern Med. 2001 Jul 17;135(2):73-87 - PubMed
  9. Circ J. 2002 Apr;66(4):311-6 - PubMed
  10. Am J Kidney Dis. 2002 Aug;40(2):227-35 - PubMed
  11. Transplant Proc. 2002 Aug;34(5):1763-6 - PubMed
  12. Lancet. 2003 Mar 8;361(9360):865-72 - PubMed
  13. Transpl Int. 2003 May;16(5):313-20 - PubMed
  14. Can J Cardiol. 2003 May;19(6):701-4 - PubMed
  15. Am J Cardiol. 2004 Jan 15;93(2):240-3 - PubMed
  16. Pharmacogenetics. 2004 Jan;14(1):53-60 - PubMed
  17. Circulation. 2004 Aug 10;110(6):724-31 - PubMed
  18. BMC Med Genet. 2004 Sep 10;5:23 - PubMed
  19. BMJ. 2004 Oct 9;329(7470):828 - PubMed
  20. S Afr Med J. 1992 Feb 15;81(4):183-5 - PubMed
  21. BMJ. 1991 Jun 22;302(6791):1481-2 - PubMed
  22. J Clin Invest. 1990 Oct;86(4):1343-6 - PubMed
  23. N Engl J Med. 1991 Aug 1;325(5):293-302 - PubMed
  24. N Engl J Med. 1987 Jun 4;316(23):1429-35 - PubMed
  25. J Am Coll Cardiol. 1983 Oct;2(4):755-63 - PubMed
  26. JAMA. 1995 May 10;273(18):1450-6 - PubMed
  27. J Am Coll Cardiol. 1995 Jun;25(7):1622-6 - PubMed
  28. JAMA. 1995 Feb 1;273(5):408-12 - PubMed
  29. J Hypertens. 1995 Dec;13(12 Pt 2):1602-9 - PubMed
  30. Lancet. 1997 Jun 28;349(9069):1857-63 - PubMed
  31. Lancet. 1997 Jun 21;349(9068):1787-92 - PubMed
  32. Coron Artery Dis. 1997 May;8(5):283-91 - PubMed
  33. J Hypertens. 1997 Dec;15(12 Pt 2):1579-92 - PubMed
  34. Kidney Blood Press Res. 1998;21(1):66-9 - PubMed
  35. Diabetes. 1998 Sep;47(9):1507-11 - PubMed
  36. Lancet. 1998 Oct 17;352(9136):1252-6 - PubMed
  37. J Cardiovasc Pharmacol. 1998 Dec;32(6):988-94 - PubMed

Publication Types